The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 26, 2022
Filed:
Jun. 22, 2019
Ohio State Innovation Foundation, Columbus, OH (US);
Hendrix College, Conway, AR (US);
John C. Byrd, Columbus, OH (US);
Thomas E. Goodwin, Conway, AR (US);
Ola Elgamal, Columbus, OH (US);
Erin Hertlein, Columbus, OH (US);
Mouad Abdulrahim, Conway, AR (US);
Chad E. Bennett, Powell, OH (US);
Sandip Madhukar Vibhute, Columbus, OH (US);
Ohio State Innovation Foundation, Columbus, OH (US);
Hendrix College, Conway, AR (US);
Abstract
Disclosed herein are compounds, 3,4,6,8-substituted-2-([1'-biphenyl]-4-yl)quinoline analogs, that are inhibitors of dihydroorotate dehydrogenase (DHODH) with improved pharmacokinetic properties. The disclosed compounds can be used in the treatment of a variety of disorders and diseases in which inhibition of DHODH can be clinically useful, including cancer, such as a hematological cancer, including acute myeloid leukemia (AML); graft-versus-host-diseases; autoimmune disorders; and disorders associated with T-cell proliferation. The disclosed compounds can demonstrate flip-flop kinetics when administered orally, i.e., pharmacokinetics in which the rate of absorption, rather than the rate of elimination, dominates the pharmacokinetics. The disclosed compounds can demonstrate a sustained pharmacokinetic profile instead of an immediate release profile. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.